Ypsomed Holding AG YPSN

Morningstar Rating
CHF 360.80 −5.20 (1.42%)
View Full Chart

Company Report

Ypsomed: Platform-Based Device Model Positions It to Capture Biologics Growth Tailwind

Ypsomed is a manufacturer of drug delivery devices for self-injection, specializing in injection pens, autoinjectors, and wearable injectors. Its devices deliver a broad range of liquid therapeutics, from established small-molecule drugs such as insulin to large-molecule biologics and the emerging class of GLP-1 receptor agonists for weight management and metabolic disease.

Price vs Fair Value

YPSN is trading at a LOCK|Hx^Pb premium.
Price
CHF 360.80
Fair Value
LOCK|!C
Uncertainty
LOCK|tw$
1-Star Price
LOCK|%.R^
5-Star Price
LOCK|J.^
Economic Moat
LOCK|wF>l
Capital Allocation
LOCK|nn%>$>Y

Bulls Say, Bears Say

Bulls

Ypsomed benefits from several secular growth drivers, including rising biologics development requiring injectables, expanding biosimilars, and surging GLP-1 drug demand.

Bears

Ypsomed and SHL Medical's focus on large-volume drugs could leave smaller biotech companies underserved, creating an opening for smaller competitors to gain traction.

Trading Information

Previous Close Price
CHF 366.00
Day Range
CHF 356.00–366.00
52-Week Range
CHF 260.50–418.00
Bid/Ask
CHF 0.00 / CHF 369.00
Shares Outstanding
13.15M
Market Cap
CHF 4.74B
Volume/Avg
10,612 / 14,754

Key Statistics

Price/Earnings (Normalized)
27.28
Price/Sales
6.72
Dividend Yield (Trailing)
1.22%
Dividend Yield (Forward)
1.22%
Dividend Payment Schedule
Jul
Total Yield
4.38%

Company Profile

Ypsomed, based in Burgdorf, Switzerland, develops and manufactures self-injection devices like pens, autoinjectors, and infusion systems for global pharma and biotech companies. The company shifted focus to business-to-business injection systems, divesting its diabetes care segment to supply device platforms to pharma partners.The company operates in a market driven by strong growth in biologics, biosimilars, patient self-administration, and GLP-1 therapies for obesity. To meet demand, Ypsomed has embarked on an ambitious capacity expansion program, with capital expenditure reaching approximately 50% of sales in recent years. This investment is partially derisked through customer co-financing, which aligns incentives and secures future volume commitments before launch.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Mid Growth
Total Number of Employees
2,099

Competitors

Valuation

Metric
YPSN
BDX
STVN
Price/Earnings (Normalized)
27.2813.7033.18
Price/Book Value
6.341.993.08
Price/Sales
6.722.513.82
Price/Cash Flow
19.1813.4418.48
Price/Earnings
YPSN
BDX
STVN

Financial Strength

Metric
YPSN
BDX
STVN
Quick Ratio
0.740.361.08
Current Ratio
1.070.941.61
Interest Coverage
76.553.5333.87
Quick Ratio
YPSN
BDX
STVN

Profitability

Metric
YPSN
BDX
STVN
Return on Assets (Normalized)
13.64%4.97%6.21%
Return on Equity (Normalized)
23.71%10.63%10.50%
Return on Invested Capital (Normalized)
18.06%7.26%8.24%
Return on Assets
YPSN
BDX
STVN

Medical Instruments & Supplies Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Intuitive Surgical Inc
ISRG
LOCK|$%ht<fTLOCK|#f$142B
Becton Dickinson & Co
BDX
LOCK|$skLOCK|jt^D$49B
ResMed Inc
RMD
LOCK|sB&GGC@LOCK|z>C>W$32B
Medline Inc Ordinary Shares - Class A
MDLN
LOCK|!$M$h@#LOCK|Nx@l$31B
Alcon Inc
ALC
LOCK|xHckKVLOCK|f!V&K$31B
West Pharmaceutical Services Inc
WST
LOCK|&LhXk^XLOCK|h>$$26B
Solventum Corp
SOLV
LOCK|NXGY?^!LOCK|qXd$15B
Baxter International Inc
BAX
LOCK|spLOCK|#@$zS$12B
The Cooper Companies Inc
COO
LOCK|CYv<#gfLOCK|!Rv%^$11B
Align Technology Inc
ALGN
LOCK|Fb@>fCLOCK|zfLS$10B

Sponsor Center